ArticleJTO clinical and research reports2024
Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study.
Yuki Katayama et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.